Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)

Dianthus Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$336.7 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 93.09% year-over-year to -$336.7 million; the TTM figure through Dec 2025 stood at -$336.7 million (down 93.09% YoY), while the FY2025 annual figure was -$336.7 million, down 93.09% from the prior year.
• Retained Earnings was -$336.7 million for Q4 2025 at Dianthus Therapeutics, down from -$272.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $47000.0 in Q4 2023 to a low of -$434.5 million in Q2 2023.
• Historically, Retained Earnings has averaged -$181.2 million across 5 years, with a median of -$160.2 million in 2024.
• The sharpest annual moves came in 2021 and 2023: Retained Earnings sank 785420.51% in 2021, then soared 100.1% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$30000.0 in 2021, then slumped by 152793.33% to -$45.9 million in 2022, then soared by 100.1% to $47000.0 in 2023, then slumped by 371146.81% to -$174.4 million in 2024, then tumbled by 93.09% to -$336.7 million in 2025.
• The last three Retained Earnings figures came in at -$336.7 million (Q4 2025), -$272.3 million (Q3 2025), and -$235.5 million (Q2 2025), per Business Quant data.